<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35801347</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Human Endogenous Retrovirus K Envelope in Spinal Fluid of Amyotrophic Lateral Sclerosis Is Toxic.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>561</EndPage><MedlinePgn>545-561</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26452</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Human endogenous retroviruses have been implicated in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Expression of human endogenous retrovirus K (HERV-K) subtype HML-2 envelope (Env) in human neuronal cultures and in transgenic mice results in neurotoxicity and neurodegeneration, and mice expressing HML-2 Env display behavioral and neuromuscular characteristics resembling ALS. This study aims to characterize the neurotoxic properties of HML-2 Env.</AbstractText><AbstractText Label="METHODS">Env neurotoxicity was detected in ALS cerebrospinal fluid and confirmed using recombinant Env protein in a cell-based assay and a mouse model. The mechanism of neurotoxicity was assessed with immunoprecipitation followed by mass spectrometry and Western blot, and by screening a panel of inhibitors.</AbstractText><AbstractText Label="RESULTS">We observed that recombinant HML-2 Env protein caused neurotoxicity resulting in neuronal cell death, retraction of neurites, and decreased neuronal electrical activity. Injection of the Env protein into the brains of mice also resulted in neuronal cell death. HML-2 Env protein was also found in the cerebrospinal fluid of patients with sporadic ALS. The neurotoxic properties of the Env and the cerebrospinal fluid could be rescued with the anti-Env antibody. The Env was found to bind to CD98HC complexed to &#x3b2;1 integrin on the neuronal cell surface. Using a panel of compounds to screen for their ability to block Env-induced neurotoxicity, we found that several compounds were protective and are linked to the &#x3b2;1 integrin pathway.</AbstractText><AbstractText Label="INTERPRETATION">HERV-K Env is released extracellularly in ALS and causes neurotoxicity via a novel mechanism. Present results pave the way for new treatment strategies in sporadic ALS. ANN NEUROL 2022;92:545-561.</AbstractText><CopyrightInformation>&#xa9; 2022 Geneuro Innovation SAS. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>NeuroTherapeutics Development Unit, Translational Neuroscience Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachani</LastName><ForeName>Muzna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroTherapeutics Development Unit, Translational Neuroscience Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Nasir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NeuroTherapeutics Development Unit, Translational Neuroscience Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMarino</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenxue</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>Kevon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Myoung-Hwa</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalak</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Proteomics Unit, Translational Neuroscience Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhaskar</LastName><ForeName>Manju</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroTherapeutics Development Unit, Translational Neuroscience Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doucet-O'Hare</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Montojo</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0664-3480</Identifier><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowen</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reoma</LastName><ForeName>Lauren Bowen</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>R&amp;D division, GeNeuro Innovation, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunel</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>R&amp;D division, GeNeuro Innovation, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierquin</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>R&amp;D division, GeNeuro Innovation, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charvet</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>R&amp;D division, GeNeuro Innovation, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perron</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2551-7685</Identifier><AffiliationInfo><Affiliation>R&amp;D division, GeNeuro Innovation, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GeNeuro, Plan-les-Ouates, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Avindra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0927-5855</Identifier><AffiliationInfo><Affiliation>Section for Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA NS003130</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003149</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015686">Gene Products, env</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019012">Integrin beta1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020077" MajorTopicYN="Y">Endogenous Retroviruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015686" MajorTopicYN="N">Gene Products, env</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019012" MajorTopicYN="N">Integrin beta1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>GeNeuro has a joint patent with National Institute of Neurological Disorders and Stroke on the antibody to HERV&#x2010;K envelope protein (US patent number 10,981,977).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35801347</ArticleId><ArticleId IdType="mid">NIHMS1822178</ArticleId><ArticleId IdType="pmc">PMC9489628</ArticleId><ArticleId IdType="doi">10.1002/ana.26452</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garcia&#x2010;Montojo M, Doucet&#x2010;O'Hare T, Henderson L, Nath A. Human endogenous retrovirus&#x2010;K (HML&#x2010;2): a comprehensive review. Crit Rev Microbiol 2018;44:715&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342650</ArticleId><ArticleId IdType="pubmed">30318978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kury P, Nath A, Creange A, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med 2018;24:379&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185488</ArticleId><ArticleId IdType="pubmed">29551251</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan R, Chiu IM, Wong JF, et al. A new class of endogenous human retroviral genomes. Science 1985;228:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">2408338</ArticleId></ArticleIdList></Reference><Reference><Citation>Flockerzi A, Ruggieri A, Frank O, et al. Expression patterns of transcribed human endogenous retrovirus HERV&#x2010;K(HML&#x2010;2) loci in human tissues and the need for a HERV transcriptome project. BMC Genomics 2008;9:354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525661</ArticleId><ArticleId IdType="pubmed">18664271</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt K, Heyne K, Roemer K, et al. HERV&#x2010;K(HML&#x2010;2) rec and np9 transcripts not restricted to disease but present in many normal human tissues. Mobile DNA 2015;6:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351823</ArticleId><ArticleId IdType="pubmed">25750667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlhardt S, Seifert M, Schneider J, et al. Human endogenous retrovirus HERV&#x2010;K(HML&#x2010;2) rec expression and transcriptional activities in normal and rheumatoid arthritis synovia. J Rheumatol 2006;33:16&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16395745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs NV, Kraft M, Tondera C, et al. Expression of the human endogenous retrovirus (HERV) group HML&#x2010;2/HERV&#x2010;K does not depend on canonical promoter elements but is regulated by transcription factors Sp1 and Sp3. J Virol 2011;85:3436&#x2013;3448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067833</ArticleId><ArticleId IdType="pubmed">21248046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Medynets M, Johnson KR, et al. Regulation of stem cell function and neuronal differentiation by HERV&#x2010;K via mTOR pathway. Proc Natl Acad Sci U S A 2020;117:17842&#x2013;17853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395438</ArticleId><ArticleId IdType="pubmed">32669437</ArticleId></ArticleIdList></Reference><Reference><Citation>Grow EJ, Flynn RA, Chavez SL, et al. Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells. Nature 2015;522:221&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503379</ArticleId><ArticleId IdType="pubmed">25896322</ArticleId></ArticleIdList></Reference><Reference><Citation>Buscher K, Hahn S, Hofmann M, et al. Expression of the human endogenous retrovirus&#x2010;K transmembrane envelope, rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res 2006;16:223&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16718269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lower R, Lower J, Frank H, et al. Human teratocarcinomas cultured in vitro produce unique retrovirus&#x2010;like viruses. J Gen Virol 1984;65(Pt 5):887&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">6202829</ArticleId></ArticleIdList></Reference><Reference><Citation>Perron H, Lalande B, Gratacap B, et al. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991;337:862&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">1707471</ArticleId></ArticleIdList></Reference><Reference><Citation>Perron H, Garson JA, Bedin F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The collaborative research group on multiple sclerosis. Proc Natl Acad Sci U S A 1997;94:7583&#x2013;7588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23865</ArticleId><ArticleId IdType="pubmed">9207135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer D, Gruchot J, Weyers V, et al. pHERV&#x2010;W envelope protein fuels microglial cell&#x2010;dependent damage of myelinated axons in multiple sclerosis. Proc Natl Acad Sci U S A 2019;116:15216&#x2013;15225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660731</ArticleId><ArticleId IdType="pubmed">31213545</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebold M, Derfuss T. The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis. Ther Adv Neurol Disord 2019;12:1756286419833574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407165</ArticleId><ArticleId IdType="pubmed">30873219</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res 2013;99:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723705</ArticleId><ArticleId IdType="pubmed">23707220</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol 2011;69:141&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Garson JA, Usher L, Al&#x2010;Chalabi A, et al. Quantitative analysis of human endogenous retrovirus&#x2010;K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV&#x2010;K RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2019;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421708</ArticleId><ArticleId IdType="pubmed">30885274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer J, Harz C, Sanchez L, et al. Transcriptional profiling of HERV&#x2010;K(HML&#x2010;2) in amyotrophic lateral sclerosis and potential implications for expression of HML&#x2010;2 proteins. Mol Neurodegener 2018;13:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091006</ArticleId><ArticleId IdType="pubmed">30068350</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Iacoangeli A, Adey BN, et al. A HML6 endogenous retrovirus on chromosome 3 is upregulated in amyotrophic lateral sclerosis motor cortex. Sci Rep 2021;11:14283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8275748</ArticleId><ArticleId IdType="pubmed">34253796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee MH, Henderson L, et al. Human endogenous retrovirus&#x2010;K contributes to motor neuron disease. Sci Transl Med 2015;7:307ra153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou A, Shaltouki A, Steiner JP, et al. Functional screening assays with neurons generated from pluripotent stem cell&#x2010;derived neural stem cells. J Biomol Screen 2014;19:32&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">24019252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A, Slagle B, Wolinsky JS. Anti&#x2010;idiotypic antibodies to rubella virus. Arch Virol 1989;107:159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">2803003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596:583&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, et al. UCSF chimera&#x2014;a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605&#x2013;1612</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:595&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Dembny P, Newman AG, Singh M, et al. Human endogenous retrovirus HERV&#x2010;K(HML&#x2010;2) RNA causes neurodegeneration through toll&#x2010;like receptors. JCI Insight 2020;5:e131093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205273</ArticleId><ArticleId IdType="pubmed">32271161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002;186:S193&#x2013;S198.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424697</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Identification, characterization, and comparative genomic distribution of the HERV&#x2010;K (HML&#x2010;2) group of human endogenous retroviruses. Retrovirology 2011;8:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228705</ArticleId><ArticleId IdType="pubmed">22067224</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrey F, Closs EI, Wagner CA, et al. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 2004;447:532&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">14770310</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander SPH, Kelly E, Mathie A, et al. The concise guide to pharmacology 2019/20: transporters. Br J Pharmacol 2019;176:S397&#x2013;S493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6844579</ArticleId><ArticleId IdType="pubmed">31710713</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Ballina LR, Cano&#x2010;Crespo S, Gonzalez&#x2010;Munoz E, et al. Amino acid transport associated to cluster of differentiation 98 heavy chain (CD98hc) is at the cross&#x2010;road of oxidative stress and amino acid availability. J Biol Chem 2016;291:9700&#x2013;9711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4850307</ArticleId><ArticleId IdType="pubmed">26945935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano&#x2010;Crespo S, Chillaron J, Junza A, et al. CD98hc (SLC3A2) sustains amino acid and nucleotide availability for cell cycle progression. Sci Rep 2019;9:14065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773781</ArticleId><ArticleId IdType="pubmed">31575908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenczik CA, Zent R, Dellos M, et al. Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem 2001;276:8746&#x2013;8752.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121428</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Li X, Li C, et al. SLC3A2 is a novel endoplasmic reticulum stress&#x2010;related signaling protein that regulates the unfolded protein response and apoptosis. PLoS One 2018;13:e0208993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310261</ArticleId><ArticleId IdType="pubmed">30592731</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander SP, Benson HE, Faccenda E, et al. The concise guide to pharmacology 2013/14: transporters. Br J Pharmacol 2013;170:1706&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3892292</ArticleId><ArticleId IdType="pubmed">24528242</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Reest J, Lilla S, Zheng L, et al. Proteome&#x2010;wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress. Nat Commun 2018;9:1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910380</ArticleId><ArticleId IdType="pubmed">29679077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasada M, Iyoda T, Asayama T, et al. Inactivation of beta1 integrin induces proteasomal degradation of Myc oncoproteins. Oncotarget 2019;10:4960&#x2013;4972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697639</ArticleId><ArticleId IdType="pubmed">31452837</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Seiki T, Asada M, et al. Alpha6beta1 integrin induces proteasome&#x2010;mediated cleavage of erbB2 in breast cancer cells. Oncogene 2003;22:831&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>